Prosecution Insights
Last updated: October 02, 2026
Application No. 17/702,643

VARIANT NUCLEIC ACID LIBRARIES FOR TIGIT

Final Rejection §102
Filed
Mar 23, 2022
Priority
Mar 24, 2021 — provisional 63/165,651
Examiner
GROSS, CHRISTOPHER M
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
TWIST BIOSCIENCE Corporation
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
425 granted / 669 resolved
+3.5% vs TC avg
Strong +40% interview lift
Without
With
+40.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
26 currently pending
Career history
699
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
29.3%
-10.7% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 669 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Responsive to reply of 5/5/2026 Claims pending 1,4-9,12-20 Claims withdrawn 18-20 Claims currently under consideration 1,4-9,12-17 Priority The present application has a filing date of 03/23/2022 and has PRO 63/165,651 filed 03/24/2021. Withdrawn Objection(s) and/or Rejection(s) All rejections from the previous action are hereby withdrawn in light of Applicant’s amendments. Allowable Subject Matter Claims 1,4-8 are allowed. New Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 9,12-17 are rejected under 35 U.S.C. 102(a)(1 & 2) as being anticipated by Piasecki et al (US AppPub 20200062859). Piasecki et al teach throughout the document and especially the abstract and paragraph 0384, diabodies or antibodies that bind TIGT with an affinity less than 5 nanomolar, whereas in document claims 256-257, Piasecki et al disclose a humanized antibody with a heavy chain comprising FTFSTYAMS of present SEQ ID 250 corresponding to SEQ ID 40 therein. The foregoing reads on claims 9,12,13,14,15,16 and 17. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M GROSS whose telephone number is (571)272-4446. The examiner can normally be reached M-F 10-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached on (571)272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER M GROSS/ Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Mar 23, 2022
Application Filed
Feb 05, 2026
Non-Final Rejection mailed — §102
May 05, 2026
Response Filed
Jul 14, 2026
Final Rejection mailed — §102
Oct 01, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742198
BIOCHIP AND MANUFACTURING METHOD THEREFOR
5y 5m to grant Granted Sep 22, 2026
Patent 12736540
METHODS FOR IDENTIFYING MODIFICATIONS OF A POLYPEPTIDE
1y 9m to grant Granted Sep 15, 2026
Patent 12723059
Multicyclic Peptides and Methods for Their Preparation
4y 11m to grant Granted Sep 01, 2026
Patent 12704509
SYSTEMS AND METHODS FOR BEAD-BASED ASSAYS IN FERROFLUIDS
4y 7m to grant Granted Aug 11, 2026
Patent 12699100
DEEP LEARNING SYSTEM FOR PREDICTING THE T CELL RECEPTOR BINDING SPECIFICITY OF NEOANTIGENS
3y 4m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+40.2%)
4y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 669 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month